Across TCGA pan-cancer cohorts, KAZN mass-spec protein differs between tumor and matched normal tissue in 4 of 18 cancer types tested, making tumor–normal expression one of KAZN’s most consistent transcriptional readouts.

The strongest signal is observed in head and neck squamous cell carcinoma (HNSC), where KAZN mass-spec protein is repressed in tumor relative to normal tissue. In most cancer types KAZN is over-expressed in tumor, although a few such as HNSC and LUAD show the opposite, repressed pattern.

HNSC, LUAD, and LSCC are the cancer types where KAZN tumor–normal differential expression is most reproducible.

mass-spec protein tumor vs normal associations by lineage

Ranked by sampling consensus. Fold-change is the tumor-versus-normal difference in KAZN mass-spec protein (log₂); positive values indicate higher expression in tumor. p-values are from the differential-expression test.

Lineage	Gender	Stage	Fold-change	p	Sampling consensus
HNSC	Male	IV	−0.686	<.001	11	view →
LUAD	Male	II,III,IV	−0.706	<.001	9	view →
LSCC	Female	III,IV	−0.687	<.001	9	view →
PDAC	Male	All	+0.090	.029	1	view →

Pink = over-expressed in tumor, green = repressed in tumor. Showing the 4 strongest of 4 lineages.

Exploration

Same gene, other analysis: KAZN RNA expression & survival · all KAZN data types